Healthcare / BiotechnologyNasdaqGS
$2.07
-0.09 (-4.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-186.5M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$230M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-466.3%
↓Gross Margin
N/A
•Debt/Equity
1.18
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+28.3%
FCF CAGR
—
FCF margin
-874.7%
FCF / Net income
1.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21.0M · net income $-142.9M · FCF $-184.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $21.0M | $21.0M | $100.6M | $97.1M | $133.6M | $207.1M | $21.1M | $21.2M | $27.5M | $2.9M |
| Net Income | $-142.9M | $-142.9M | $-119.0M | $-130.4M | $-133.3M | $-36.3M | $-190.2M | $-105.4M | $-52.2M | $-32.5M |
| EBITDA | $-146.3M | $-146.3M | $-136.2M | $-142.9M | $-129.4M | $-31.0M | $-189.3M | $-110.6M | $-56.3M | $-32.0M |
| EPS | -1.39 | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | — | — | — |
| Operating Margin | -741.3% | -741.3% | -144.2% | -156.3% | -103.2% | -18.0% | -925.1% | -539.2% | -208.3% | -1137.8% |
| Net Margin | -679.2% | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | -901.6% | -496.7% | -189.9% | -1130.9% |
| Balance Sheet | ||||||||||
| Debt/Equity | 1.18 | 1.18 | 0.34 | 0.29 | 0.20 | — | — | — | — | — |
| Current Ratio | 5.25 | 5.25 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-184.1M | $-184.1M | $-231.2M | $-186.5M | $-24.4M | $295.3M | $-171.8M | $-114.6M | $125.6M | $-18.6M |
| Returns | ||||||||||
| ROE | -466.3% | -466.3% | -93.9% | -97.2% | -62.2% | -12.1% | -71.1% | -54.1% | 53.6% | 62.4% |
| Valuation | ||||||||||
| P/B | 6.96 | 6.96 | 1.57 | 4.67 | 3.17 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | -79.1% | -79.1% | 3.6% | -27.4% | — | 881.5% | -0.6% | -22.9% | 857.8% | — |
| EPS Growth | -13.0% | -13.0% | 21.2% | 3.7% | — | 81.6% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+55.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.23 → -1.39
Residual
+55.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.